Mounjaro Outperforms Wegovy in Weight Loss Drug Trial

story

MAY 14

Above: Slimming syringes of the brands "Wegovy", "Ozempic," and "Mounjaro" are sold in the Achat pharmacy in Mitte, Berlin, Germany, on July 11, 2024. Image copyright: Jens Kalaene/Contributor/picture alliance via Getty Images

story last updated MAY 15

The Spin

Pro-establishment narrative

Weight loss drugs have made historic leaps and bounds in the fight to end obesity, now rivaling surgery's impact. While Mounjaro leads with 25% weight loss, Wegovy's 14% reduction is no small feat either. That said, side effects like nausea and muscle loss highlight risks. Ongoing research is vital to ensure these miracle drugs are as safe as possible, cementing their revolutionary role in tackling the global obesity crisis.

The Independent The i Paper

Establishment-critical narrative

Mounjaro and Wegovy are certainly groundbreaking for obesity, but will never be cures. Not only do they contain side effects like nausea and muscle loss, but they dodge the real issue: a food system pushing processed junk. Natural, whole foods can keep everyone in better shape, especially those genetically prone to obesity. Of course, research must continue to refine drug safety, but diet reform will always trump pharmaceutical fixes.

Guardian American Conservative

Metaculus Prediction

Articles on this story

The toxic debate about obesity rages on. But at least we know if Mounjaro or Wegovy is better for weight loss | Zoe Williams